Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma

Journal of the Medical Association of Thailand

Volumn 91, Issue 12, 2008, Pages 1779-1785

  Suthipintawong, Cheepsumon ^a   Wejaranayang, Charnyut ^a   Vipupinyo, Chroen ^a  

^a RAJAVITHI HOSPITAL   (Thailand)

Author keywords

C erbb 2; Endometrial carcinoma; ER; Ki 67; P53; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; ONCOGENE; ONCOGENE C ERB; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SURVIVAL; THAILAND;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL; THAILAND; TUMOR MARKERS, BIOLOGICAL;

EID: 58949094470     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Martin N, Patel N. Cancer incidence and leading sites. In: Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V Cheirsilpa A, et al, editors. Cancer in Thailand. Vol. III, 1995-1997. Bangkok: Bangkok Medical Publisher; 2000: 9-18.
2. Farley JH, Nycum LR Birrer M J, Park RC, Taylor R R. Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2000; 79: 86-9.
3. Abeler V M, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992; 2: 9-22.
4. Ayhan A, Taskiran C, Yuce K, Kucukali T. The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma. Int J Gynecol Pathol 2003; 22: 71-4.
5. Zaino R J, Silverberg S G, Norris H J, Bundy BN, Morrow CP, Okagaki T. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 1994; 13: 29-36.
6. Stefansson I M, Salvesen H B, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004; 44: 472-9.
7. Zaino RJ, Kurman R J, Diana K L, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage - a Gynecologic Oncology Group study. Cancer 1996; 77: 1115-21.
8. Carcangiu ML, Chambers J T, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol 1990; 94: 247-54.
9. Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990; 38: 59-65.
10. Iwai K, Fukuda K, Hachisuga T, Mori M, Uchiyama M, Iwasaka T, et al. Prognostic significance of
11. progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma. Gynecol Oncol 1999; 72: 351-9.
12. Nyholm H C, Nielsen A L, Lyndrup J, Dreisler A, Thorpe S M. Estrogen and progesterone receptors in endometrial carcinoma: comparison of immuno- histochemical and biochemical analysis. Int J Gynecol Pathol 1993; 12: 246-52.
13. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 220-5.
14. Kallakury BV, Ambros R A, Hayner-Buchan AM, Sheehan C E, Malfetano J H, Ross J S. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 1998; 17: 320-6.
15. Ikawa S, Sano T, Furumoto H, Aono T. Multidirectional differentiation of endometrial carcinoma with special reference to tumor aggressiveness evaluated by Ki-67 expression. Gynecol Oncol 1999; 72: 323-30.
16. Geisler J P, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow- up. Gynecol Oncol 1999; 75: 432-6.
17. Cao Q J, Einstein M H, Anderson PS, Runowicz CD, Balan R, Jones J G. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 2002; 21: 147-54.
18. Risberg B, Karlsson K, Abeler V, Lagrelius A, Davidson B, Karlsson MG. Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. Int J Gynecol Pathol 2002; 21: 155-60.
19. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 1996; 15: 202-8.
20. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks C B. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129-37.
21. Saffari B, Jones LA, el Naggar A, Felix J C, George J, Press M F. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995; 55: 5693-8.
22. Rolitsky CD, Theil K S, McGaughy V R, Copeland L J, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999; 18: 138-43.
23. Mikuta J J. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 1993; 71: 1460-3.
24. Scully RE, Bonfiglio TA, Kurman R J, Silverberg S G, Wilkinson E J. World Health Organization. International histological classification of tumors. Histological typing of female genital tract tumors. New York: Springer- Verlag; 1994.
25. Salvesen H B, Iversen O E, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999; 17: 1382-90.
26. Creasman W T, Soper JT, McCarty KS Jr, McCarty K S Sr, Hinshaw W, Clarke-Pearson DL. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985; 151: 922-32.
27. Chambers J T, Carcangiu ML, Voynick I M, Schwartz P E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 1990; 94: 255-60.
28. Suzuki C, Matsumoto T, Sonoue H, Arakawa A, Furugen Y, Kinoshita K. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol Int 2003; 53: 495-500.
29. Shiozawa T, Xin L, Nikaido T, Fujii S. Immuno- histochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecol Pathol 1997; 16: 348-53.
30. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer 2002; 12: 286-9.
31. Cirisano F D, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996; 3: 99-105.
32. Borst MP, Baker V V, Dixon D, Hatch K D, Shingleton H M, Miller DM. Oncogene alterations in endometrial carcinoma. Gynecol Oncol 1990; 38: 364-6.
33. Hetzel D J, Wilson TO, Keeney G L, Roche PC, Cha S S, Podratz K C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47: 179-85.
34. Bigsby R M, Li AX, Bomalaski J, Stehman F B, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992; 79: 95-100.
35. Leong T Y, Leong AS. Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol 2006; 13: 63-9.